Images List Premium Download Classic

Pharmaceutically Acceptable Salts

Pharmaceutically Acceptable Salts-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Soluble guanylate cyclase stimulators
June 22, 2017 - N°20170174693

Or a pharmaceutically acceptable salts thereof, wherein x, y, z, r1, r2, r4, ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cgmp”), and are generally suitable for the therapy and prophylaxis of diseases which are associated ...
NEW Inhibitors of cyclin-dependent kinase 7 (cdk7)
Syros Pharmaceuticals, Inc.
June 22, 2017 - N°20170174692

The present invention provides novel compounds described herein, such as of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, ...
NEW Substituted indoles
Syros Pharmaceuticals, Inc.
June 22, 2017 - N°20170174688

Wherein r1, r2, r3, r4, r5, and r6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by suv420h1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (i).
NEW Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Pyrazolone compounds and uses thereof
Inception 2, Inc.
June 22, 2017 - N°20170174666

The invention disclosed herein is directed to compounds of formula i [formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of formula ...
NEW Primary carboxamides as btk inhibitors
Inception 2, Inc.
June 22, 2017 - N°20170174624

Pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
NEW Composition for preventing or treating muscle wasting-related disease and use thereof
Samsung Electronics Co., Ltd.
June 22, 2017 - N°20170173064

Provided is a pharmaceutical composition for preventing or treating a muscle wasting-related disease of a subject, the composition including one or more compounds selected from the group consisting of isotretinoin, vismodegib, and lincomycin, pharmaceutically acceptable salts, stereoisomers, derivatives, or solvates thereof, or combinations thereof, and a method of preventing or treating a muscle wasting-related disease using the same.
NEW Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Pyridazinone compounds and their use as daao inhibitors
Takeda Pharmacuetical Company Ltd.
June 22, 2017 - N°20170173007

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein r1 and r2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
NEW Particulate materials
Nektar Therapeutics
June 22, 2017 - N°20170173006

Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μ...
NEW Methods for treating inflammatory conditions
Melior Discovery, Inc.
June 22, 2017 - N°20170173004

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.
NEW Antimitotic amides for the treatment of cancer and proliferative disorders
Frost Biologic, Inc.
June 22, 2017 - N°20170172984

Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of formula i where ar, r5, r6, r8, r9, r11, x1, and x2 are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.
Chalcone-urea derivatives as insulin sensors
National University Of Singapore
June 15, 2017 - N°20170168073

The invention relates to compounds of formula (i) or derivatives, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites or prodrugs thereof, in which the substituents are as defined in the specification. These compounds may be useful as insulin sensors; in insulin secretion studies and as probes for insulin detection.
Cephem compounds, their production and use
Naeja-rgm Pharmaceuticals Inc.
June 15, 2017 - N°20170166587

Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through ...
Process for making tetracyclic heterocycle compounds
Msd R&d (china) Co., Ltd
June 15, 2017 - N°20170166586

The present invention is directed to a process for making tetracyclic heterocycle compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein x1, x2, r1, r2 and r3 are defined above herein. The present invention is also directed to compounds that are useful as synthetic intermediates in the process of the invention.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Ire-1alpha inhibitors
Mannkind Corporation
June 15, 2017 - N°20170166576

The invention provides compounds which directly inhibit ire-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Substituted spirocyclic inhibitors of autotaxin
X-rx, Inc.
June 15, 2017 - N°20170166568

The present invention relates to compounds according to formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by atx.
Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions
Takeda Pharmaceutical Company Limited
June 15, 2017 - N°20170166553

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, in which r1, r2, r3, r4 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
Korea University Research And Business Foundation
June 15, 2017 - N°20170166505

The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory ...
Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
Pharmathen S.a.
June 15, 2017 - N°20170165315

The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
Topical formulations of heparin
Troikaa Pharmaceuticals Limited
June 15, 2017 - N°20170165291

The present invention relates to advanced topical formulations of pharmaceutically acceptable salts of heparin providing enhanced transdermal penetration. The present invention provides clear, non-sticky liquid formulations in which the drug is ready-for-absorption and which are suitable for administration in the form of a solution or a spray. The topical formulations of the present invention do not form flaky or gel-like ...
Heteroaromatic compounds and their use as dopamine d1 ligands
Troikaa Pharmaceuticals Limited
June 15, 2017 - N°20170165270

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of ...
Antimicrobial drug synthesis and therapeutic compositions
Troikaa Pharmaceuticals Limited
June 15, 2017 - N°20170165233

This invention relates to the medical use of an antimicrobial agent, racemic ornidazole, its (r) and (s) enantiomers, or pharmaceutically acceptable salts or esters thereof, and to methods of treatment which involve treating a subject with ornidazole. The racemic (rac)-ornidazole, its enantiomers, or pharmaceutically acceptable salts or esters thereof, may be used in combination with other actives. The invention ...
Loading